301257 Stock Overview
Provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
SMO ClinPlus CO.,LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥26.36 |
| 52 Week High | CN¥46.67 |
| 52 Week Low | CN¥23.07 |
| Beta | 0.92 |
| 1 Month Change | -2.23% |
| 3 Month Change | -8.15% |
| 1 Year Change | -15.60% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.09% |
Recent News & Updates
Beyond Lackluster Earnings: Potential Concerns For SMO ClinPlusLTD's (SZSE:301257) Shareholders
Nov 06
SMO ClinPlus CO.,LTD. (SZSE:301257) Held Back By Insufficient Growth Even After Shares Climb 32%
Sep 30Recent updates
Beyond Lackluster Earnings: Potential Concerns For SMO ClinPlusLTD's (SZSE:301257) Shareholders
Nov 06SMO ClinPlus CO.,LTD. (SZSE:301257) Held Back By Insufficient Growth Even After Shares Climb 32%
Sep 30Little Excitement Around SMO ClinPlus CO.,LTD.'s (SZSE:301257) Earnings As Shares Take 37% Pounding
Jun 06SMO ClinPlusLTD's (SZSE:301257) Promising Earnings May Rest On Soft Foundations
May 05Shareholder Returns
| 301257 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -0.5% | -0.7% | -0.9% |
| 1Y | -15.6% | 7.3% | 22.0% |
Return vs Industry: 301257 underperformed the CN Life Sciences industry which returned 0.5% over the past year.
Return vs Market: 301257 underperformed the CN Market which returned 18.4% over the past year.
Price Volatility
| 301257 volatility | |
|---|---|
| 301257 Average Weekly Movement | 4.9% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 4.0% |
Stable Share Price: 301257 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301257's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 4,692 | Hongwei Yang | www.smo-clinplus.com |
SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company’s SMO services include preliminary model establishment, preliminary plan preparation, initiation of clinical trial sites, on-site implementation, and project management services.
SMO ClinPlus CO.,LTD. Fundamentals Summary
| 301257 fundamental statistics | |
|---|---|
| Market cap | CN¥2.10b |
| Earnings (TTM) | CN¥106.08m |
| Revenue (TTM) | CN¥809.89m |
19.8x
P/E Ratio2.6x
P/S RatioIs 301257 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301257 income statement (TTM) | |
|---|---|
| Revenue | CN¥809.89m |
| Cost of Revenue | CN¥597.94m |
| Gross Profit | CN¥211.95m |
| Other Expenses | CN¥105.86m |
| Earnings | CN¥106.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 29, 2025
| Earnings per share (EPS) | 1.33 |
| Gross Margin | 26.17% |
| Net Profit Margin | 13.10% |
| Debt/Equity Ratio | 0% |
How did 301257 perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield18%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 10:01 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SMO ClinPlus CO.,LTD. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Siao Ye | Everbright Securities Co. Ltd. |